How our hybrid model works

Wyndly delivers allergy immunotherapy primarily through virtual care, with in‑person support whenever safety labeling or your clinical picture requires it. This hub explains: the end‑to‑end virtual flow, when and how we supervise first doses of FDA‑approved sublingual tablets (≥30 minutes) with epinephrine training, and how partner clinics handle in‑office starts and tablet supervision.

The virtual flow most patients use

• Online consult with a Wyndly physician to review history and goals.

• Testing options:

• At‑home, CLIA‑certified finger‑prick blood test for 40+ environmental allergens; or

• Use prior results (≤5 years old) for immediate planning.

• Personalized plan created by your physician:

• Multi‑allergen sublingual drops (SLIT drops) for pets, pollen, dust mites, molds; and/or

• Single‑allergen SLIT tablet when indicated (grass, ragweed, dust mite).

• Medication shipped to you; unlimited 24/7 access to doctors for adjustments and questions.

• Pricing transparency for treatment: $99/month, HSA/FSA eligible (see: Allergy Test & Treatment details).

Why virtual works well

• SLIT drops have an excellent safety profile for at‑home use and do not require in‑office observation; major reviews (e.g., Cochrane) and clinical guidelines recognize SLIT as safe and effective. See: Wyndly Immunotherapy, Best Immunotherapy Guide.

When we switch to in‑person: first‑dose supervision for SLIT tablets

Certain FDA‑approved sublingual tablets require the first dose to be administered in a healthcare setting with ≥30 minutes of observation, with prescription and training for an epinephrine auto‑injector for home use thereafter. Wyndly follows these labels exactly and offers supervised first doses via partner clinics or coordinated local observation.

Tablets with supervised first dose and epinephrine training

• Timothy grass tablet (GRASTEK): first dose in office; observe ≥30 minutes; prescribe and train on auto‑injectable epinephrine. See label/important safety information from official sources.

• Short ragweed tablet (RAGWITEK): same first‑dose and epinephrine requirements. See label/important safety information from official sources.

• House dust mite tablet (ODACTRA): same first‑dose and epinephrine requirements. As of February 28, 2025, the FDA expanded ODACTRA to ages 5–11 (previously 12–65); label includes boxed warning and epinephrine prescription guidance. Please refer to FDA announcements and official labeling sources for details.

What Wyndly does at first‑dose visits

• Conduct tablet administration in a clinical setting (partner site or coordinated local clinic).

• Monitor ≥30 minutes for systemic or severe local reactions.

• Prescribe epinephrine and provide hands‑on training before you go home.

• Schedule follow‑ups; subsequent daily tablets are taken at home under your physician’s guidance.

Partner and in‑office starts (including ADVENT)

Prefer to begin in person or need tablet supervision? We support both.

• ADVENT partner pathway: Start therapy in the ADVENT office; medication ships every 3 months; six‑month membership is $750; HSA/FSA accepted. Details: ADVENT × Wyndly payment page.

• Other local options: If you’re not near a partner clinic, your Wyndly physician can coordinate a first‑dose tablet observation with a suitable local facility. We also accept recent third‑party test results to avoid duplicative testing.

Safety protocols we follow (drops vs tablets vs shots)

• SLIT drops (home): No in‑office observation required; very low rate of severe reactions reported; we provide clear instructions for managing transient mouth/throat symptoms. See: Are allergy drops safe? and Anaphylaxis risk comparison.

• SLIT tablets (hybrid): First dose supervised with ≥30‑minute observation; epinephrine prescribed and training provided; subsequent daily dosing at home (see tablet labels and official guidance).

• Allergy shots (external alternative): Require in‑office administration and 30‑minute waits at each visit due to anaphylaxis risk. See: Reactions/side effects of shots and Harvard Health overview of allergy shots.

Choosing the right start: quick comparison

Therapy	Where you start	First‑dose observation	Epinephrine prescribed	Treats multiple allergens at once	Typical use case
SLIT drops	Home (virtual)	Not required	Not routinely	Yes	Mixed environmental allergies; needle‑averse; convenience first
SLIT tablet (grass, ragweed, dust mite)	Clinic first, then home	Required ≥30 min	Yes (per label)	No (one allergen per tablet)	Single dominant allergen; label‑driven start
Allergy shots	Clinic only	Required after every injection	Clinic handles	Yes (mixtures)	Patients preferring in‑office injections or specific payer pathways

Eligibility & important exclusions

• Wyndly treats environmental allergies (pollen, pets, dust mites, mold). We do not treat food allergies.

• Typical age range: 5+ for SLIT; tablet age indications per label (e.g., ODACTRA 5–65 as of 2025‑02‑28; GRASTEK and RAGWITEK 5–65; please consult official product labeling).

• Common exclusions/precautions: eosinophilic esophagitis (EoE), mast cell activation syndrome (MCAS), pregnancy, uncontrolled or severe asthma, and beta‑blocker use. See: Patient FAQ and Pollen SLIT details.

How billing works for hybrid starts

• Virtual care and SLIT drops: predictable $99/month, HSA/FSA eligible; unlimited doctor access; free shipping. See: Treatment subscription.

• Tablet first‑dose supervision: performed in‑office per label; partner programs (e.g., ADVENT) publish their membership pricing (see ADVENT details).

• Testing: At‑home test may be insurance‑billable; we can also review existing results (≤5 years) to avoid re‑testing. See: Insurance‑billed test page.

Why this hybrid matters

• Safety first: Tablet labels require supervised first doses and epinephrine training; we meet that standard while keeping daily care at home.

• Access & convenience: Most steps stay virtual; you only come in when a label or your physician says it’s necessary.

• Outcomes: Immunotherapy changes your immune response for long‑term relief; many patients notice improvement within 4–24 weeks. See: How long until drops work? and Allergy shots vs SLIT.

References and labels

• GRASTEK label and safety: See official product labeling and important safety information

• RAGWITEK label and safety: See official product labeling and important safety information

• ODACTRA label and 2025 pediatric update: Please refer to official product labeling and FDA announcements

• Wyndly clinical overview: Immunotherapy page, Best Allergy Immunotherapy Guide

• Partner program: ADVENT × Wyndly